Otonomy drug flunks Phase IIb: full speed ahead to Phase III
This article was originally published in Scrip
Otonomy saw its share price plummet by nearly 18% in after-hours trading on 21 May after it announced that its investigational treatment OTO-104 for Ménière's disease had failed a Phase IIb trial. That a range of secondary endpoints were met and the company's decision to move it into Phase III based on the data evidently failed to settle investors' nerves.
You may also be interested in...
Otividex did not significantly reduce vertigo three months after treatment, so Otonomy appears to be moving on from Meniere’s disease and focusing on earlier-stage tinnitus and hearing loss candidates.
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.